Though it has not yet been tested as an anti-cancer agent, PIP-S2 successfully inhibited SOX2-DNA binding by targeting the SOX2 DNA-binding sequence, thus triggering the differentiation of pluripotent stem cells [467]. Here, SOX2 is linked to cancer.